Collegeville, PA, United States of America

Xinrong Tian

This inventor holds 15 USPTO granted patents and 4 published patent applications and 10 EPO patents. Top assignees: Glaxosmithkline LLC, Glaxosmithkline Intellectual Property (No.2) Limited. Active years: 2013-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xinrong Tian. Retrieved from https://idiyas.com/inventor/xinrong-tian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 4)

% Patents Active = 13.3

EPO Patents = 10 (Patent Applications = 14)

Average Co-Inventor Count = 6.3

ph-index = 6

Forward Citations = 117(Granted Patents)

Company Filing History:

Glaxosmithkline Intellectual Property (No.2) Limited

patents

Years Active: 2013-2020

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10604531 - Enhancer of zeste homolog 2 inhibitors (2020-03-31),

2. 9790212 - Enhancer of zeste homolog 2 inhibitors (2017-10-17),

3. 9649307 - Indoles (2017-05-16),

4. 9505745 - Enhancer of zeste homolog 2 inhibitors (2016-11-29),

5. 9402836 - Indoles (2016-08-02),

6. 9346840 - Cyclopropylamines as LSD1 inhibitors (2016-05-24),

7. 9114141 - Indoles (2015-08-25),

8. 9073924 - Azaindazoles (2015-07-07),

9. 9018382 - Indazoles (2015-04-28),

10. 8975291 - Indoles (2015-03-10),

11. 8846935 - Indazoles (2014-09-30),

12. 8637509 - Azaindazoles (2014-01-28),

13. 8536179 - Indoles (2013-09-17),

14. 8415345 - Benzene sulfonamide thiazole and oxazole compounds (2013-04-09),

15. 8383635 - Chemical compounds (2013-02-26),

Title: **Inventor Xinrong Tian: Pioneering Innovations in Cancer Therapy**

Introduction

Xinrong Tian, based in Collegeville, Pennsylvania, is a prominent inventor recognized for his significant contributions to the field of pharmaceutical sciences. With a remarkable portfolio of 15 patents, Tian has focused primarily on inhibitors related to Enhancer of Zeste Homolog 2 (EZH2), which play a critical role in cancer treatment.

Latest Patents

Among his latest inventions, Tian has developed novel compounds that serve as inhibitors of Enhancer of Zeste Homolog 2 (EZH2). His first notable patent outlines compounds represented by Formula (I), which not only act as inhibitors but are also formulated for therapeutic use against various cancers. Another patent expands on this concept with compounds described in Formula (III)(a), further enhancing the pharmaceutical options available for treating malignancies. These inventions represent crucial steps forward in cancer therapeutics, showcasing Tian's commitment to advancing medical science.

Career Highlights

Throughout his career, Xinrong Tian has collaborated with leading pharmaceutical firms, most notably GlaxoSmithKline LLC and GlaxoSmithKline Intellectual Property Limited. His work in these institutions has enabled him to apply his innovative ideas and contribute substantially to drug development efforts aimed at combating cancer.

Collaborations

In the realm of research and development, Tian has partnered with esteemed colleagues such as William Henry Miller and Neil W. Johnson. These collaborations have fostered a creative environment conducive to groundbreaking discoveries and the advancement of cancer therapies.

Conclusion

Xinrong Tian stands out as a significant figure in the field of cancer research, with his numerous patents and partnerships highlighting his dedication to innovation. His work continues to inspire future developments in cancer treatment, making a lasting impact on both the scientific community and patients worldwide.

Profile summary based on public USPTO records.